CYTOPROTECTIVE THERAPY POTENTIAL IN PATIENTS WITH CHRONIC COR PULMONALE

The study investigated effectiveness and safety of a cytoprotector mexicor in patients with chronic cor pulmonale (CCP). All participants (n=56; age 38-80 years) were divided into four groups. Group I (n=16) received a standard pulmonary therapy, while Group II (n=20) also received mexicor (300 mg/d...

Full description

Bibliographic Details
Main Authors: S. A. Surotkina, A. A. Kotlyarov, N. M. Selezneva, E. N. Efremova
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2010-10-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/1495